EP
PCVX icon

Essential Partners’s Vaxcyte PCVX Stock Holding History

Essential Partners’s Portfolio PCVX Stock Details PCVX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$2.79K Buy
48
+27
+129% +$1.47K ﹤0.01% 1827
2026
Q1 		$1.22K Buy
21
+16
+320% +$869 ﹤0.01% 2182
2025
Q4 		$231 Buy
5
+3
+150% +$134 ﹤0.01% 2404
2025
Q3 		$72 Buy
+2
New +$66 ﹤0.01% 2528

Other funds holding PCVX

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
JT
Jupiter Topco New York $245B AUM
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return

Essential Partners's PCVX Position: Q2 2026 in Review

Essential Partners increased its Vaxcyte (PCVX) stake by 129% in Q2 2026, buying an estimated $1.47K and bringing the position to 48 shares worth $2.79K. The position accounts for ﹤0.01% of the portfolio, ranked #1827.

Essential Partners first reported a position in PCVX in Q3 2025 and has held it in 4 quarters since. 331 funds tracked by Wall St. Rank hold PCVX as of Q2 2026.

  • Essential Partners held 48 shares of Vaxcyte worth $2.79K as of Q2 2026.
  • Essential Partners bought 27 Vaxcyte shares in Q2 2026, an estimated $1.47K.
  • Vaxcyte made up ﹤0.01% of Essential Partners's portfolio in Q2 2026, its #1827 holding.
  • Essential Partners first reported a position in Vaxcyte in Q3 2025 and has held it in 4 quarters since.
  • 331 funds tracked by Wall St. Rank held Vaxcyte as of Q2 2026.

Based on Essential Partners's 13F filing for Q2 2026, filed 10 Aug 2026.